Back to Search
Start Over
Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates
- Source :
- Clinical Gastroenterology and Hepatology, Vol. 17, No 4 (2019) pp. 748-755.e3, Digital.CSIC. Repositorio Institucional del CSIC, instname
- Publication Year :
- 2019
- Publisher :
- Elsevier, 2019.
-
Abstract
- On Behalf of theGlobal Nonalcoholic Steatohepatitis Council.<br />[Background and Aims] Although hepatitis B and C have been the main drivers of hepatocellular carcinoma (HCC), nonalcoholic steatohepatitis (NASH) has recently become an important cause of HCC. The aim of this study was to assess the causes of HCC among liver transplant (LT) candidates in the United States.<br />[Methods] The Scientific Registry of Transplant Recipients (2002–2016) was used to estimate the trends in prevalence of HCC in LT candidates with the most common types of chronic liver disease: alcoholic liver disease (ALD), chronic hepatitis B (CHB), chronic hepatitis C, and NASH.<br />[Results] 158,347 adult LT candidates were included. Of these, 26,121 (16.5%) had HCC; this proportion increased from 6.4% (2002) to 23.0% (2016) (trend P < .0001). Over the study period, CHC remained the most common etiology for HCC (65%). The proportions of HCC accounted for by CHC and ALD remained stable (both trend P > .10), the proportion of CHB decreased 3.1-fold (P < .0001), while the proportion of NASH in HCC increased 7.7-fold (from 2.1% to 16.2%; P < .0001). Furthermore, since 2002, the prevalence of HCC in LT candidates with NASH increased 11.8-fold, while this rate increased 6.0-fold in CHB, 3.4-fold in ALD, and 2.3-fold in CHC (all P < .0001); the increasing trend in NASH was steeper than that for any other etiology (P < .0001 in a trend regression model). The proportion of LT candidates with HCC who ultimately received a transplant or died while waiting did not differ between etiologies (P > .05).<br />[Conclusions] Nonalcoholic steatohepatitis is the most rapidly growing cause of HCC among US patients listed for liver transplantation.<br />Ira M. Jacobson, Elisabetta Bugianesi, Vincent W. Wong, Manuel Romero-Gomez, and Aijaz Ahmed have received research funds and/or consultant fees from Gilead Sciences and Intercept Pharmaceuticals.
- Subjects :
- Male
Alcoholic liver disease
UNOSOPTN
medicine.medical_treatment
Liver transplantation
ddc:616.07
Chronic liver disease
Gastroenterology
DISEASE
Cohort Studies
0302 clinical medicine
OPTN
Liver Cirrhosis, Alcoholic
Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease
Prevalence
GLOBAL EPIDEMIOLOGY
RISK
ddc:616
Liver Cancer
Mortality
NAFLD
Transplant Waitlist
UNOS
Hepatology
Liver Neoplasms
FATTY LIVER
ASSOCIATION
Hepatitis B
Middle Aged
CANCER
030220 oncology & carcinogenesis
Hepatocellular carcinoma
030211 gastroenterology & hepatology
Female
Liver cancer
Adult
medicine.medical_specialty
Carcinoma, Hepatocellular
Adolescent
UNITED-STATES
NASH-CIRRHOSIS
03 medical and health sciences
Young Adult
Hepatitis B, Chronic
Internal medicine
Diabetes mellitus
medicine
Humans
neoplasms
Aged
business.industry
Hepatitis C, Chronic
medicine.disease
CRYPTOGENIC CIRRHOSIS
United States
digestive system diseases
Transplant waitlist
business
Subjects
Details
- Language :
- English
- ISSN :
- 15423565
- Database :
- OpenAIRE
- Journal :
- Clinical Gastroenterology and Hepatology, Vol. 17, No 4 (2019) pp. 748-755.e3, Digital.CSIC. Repositorio Institucional del CSIC, instname
- Accession number :
- edsair.doi.dedup.....7363242de79b5398006b1b0433c2691f